2. Search Result
Search Result
Results for "

hemolytic potential

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

3

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117930
    Danicopan
    4 Publications Verification

    ACH-4471

    		 Complement System Inflammation/Immunology
    Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
    Danicopan
  • HY-114524
    (E)-4-Oxo-2-nonenal
    1 Publications Verification

    4-ONE

    		 TRP Channel Cardiovascular Disease
    (E)-4-Oxo-2-nonenal (4-ONE) is one of the major hemolytic decomposition products of lipid hydroperoxides. (E)-4-Oxo-2-nonenal is a major product of the FeII-mediated breakdown of lipid hydroperoxides. (E)-4-Oxo-2-nonenal is a potent transient receptor potential ankyrin 1 (TRPA1) agonist .
    (E)-4-Oxo-2-nonenal
  • HY-P5016A
    CRAMP-18 (mouse) acetate

    		Antibiotic Fungal Bacterial Infection Cancer
    CRAMP-18 (mouse) acetate is an antibiotic peptide without hemolytic activity. CRAMP-18 (mouse) acetate has good inhibitory activity against Gram-negative bacteria, such as S. typhimurium and P. aeruginosa. CRAMP-18 (mouse) acetate has the potential to study antifungal, antibacterial and antitumor .
    CRAMP-18 (mouse) acetate
  • HY-178504
    Lug-15

    		Bacterial Infection
    Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .
    Lug-15
  • HY-114987
    EMD 21657

    		iGluR Neurological Disease
    EMD 21657 is a derivative of Piracetam (HY-B0585). EMD 21657 inhibits LOT compound action potential, and enhances the local anesthetic effect of Hexanol (HY-W032022). EMD 21657 exhibits hemolytic effect, and can be used in research about alcoholic encephalopathy syndrome .
    EMD 21657
  • HY-P5016
    CRAMP-18 (mouse)

    		Antibiotic Bacterial Fungal Infection Cancer
    CRAMP-18 (mouse) is an antibiotic peptide without hemolytic activity. CRAMP-18 (mouse) has good inhibitory activity against Gram-negative bacteria, such as S. typhimurium and P. aeruginosa. CRAMP-18 (mouse) has the potential to study antifungal, antibacterial and antitumor .
    CRAMP-18 (mouse)
  • HY-162923
    Antibacterial agent 244

    		Bacterial Antibiotic Infection
    Antibacterial agent 244 is an orally active compound with broad-spectrum antibacterial activity, primarily targeting Gram-positive bacteria, with a MIC value of 1–4 μg/mL and low hemolytic toxicity (HC50 of 111.6 μg/mL). Antibacterial agent 244 disrupts bacterial transmembrane potential, increases membrane permeability, leading to leakage of cellular contents such as DNA and proteins, ultimately causing bacterial death. Antibacterial agent 244 can be used in research related to Gram-positive bacterial infections .
    Antibacterial agent 244
  • HY-125459
    L 705589

    		Fungal Infection
    L-705589 is a semi-synthetic penicillin-type antifungal agent. L-705589 exerts its antifungal effect by inhibiting the 1,3-β-D-glucan synthase in the fungal cell wall. L-705589 exhibits potent bactericidal activity against various Candida species (such as Candida albicans, Candida glabrata, Candida krusei, etc.) (MFC: 0.06 - 8 μg/mL), but has relatively weak activity against Cryptococcus neoformans (MFC: 32 - 64 μg/mL). L-705589 remains active against drug-resistant Candida strains and is not prone to inducing drug resistance. L-705589 significantly improves survival rates in the model of minor invasive aspergillosis .
    L 705589
  • HY-P11615
    FuK

    		Bacterial Infection
    FuK is a WK2-analog antimicrobial peptide modified with fluorinated unnatural amino acids. FuK has an LD50 of 72.34 mg/kg in mice, shows no hemolytic activity, with high stability against trypsin, chymotrypsin, and saline environments. FuK exerts bactericidal effects by enhancing the permeability of bacterial outer membranes, inducing depolarization of cytoplasmic membranes, and disrupting membrane potential balance against bacterias such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and MRSA. FuK exhibits synergistic antimicrobial activity with polymyxin B (HY-149179), vancomycin (HY-B0671), and ciprofloxacin (HY-B0356), and also inhibits Ciprofloxacin-induced bacterial drug resistance. FuK has in vivo safety, effectively reduces bacterial load and inflammatory cell infiltration in a mouse MRSA model, and promotes collagen fiber formation in skin wounds .
    FuK

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: